iCo Therapeutics Begins Trading on the OTCQX Marketplace
December 20, 2013, Vancouver, Canadaâ€"iCo Therapeutics (TSX-V: ICO) (OTCQX: ICOTF), announced that its common
iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B
December 12, 2013, Vancouver, Canada — iCo Therapeutics (TSX-V: ICO), today announced that on
iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit
December 5, 2013, Vancouver, Canada — iCo Therapeutics (TSX-V: ICO), today announced that Management
iCo Therapeutics Announces Third Quarter 2013 Financial Results
November 27, 2013, Vancouver, Canada—iCo Therapeutics (TSX-V: ICO), today reported financial results for the
iCo Therapeutics to Present at the 6th Annual LD MICRO
November 21, 2013, Vancouver, Canada— iCo Therapeutics Inc. (TSX-V: ICO), today announced that Management
iCo Therapeutics Announces Warrant Exercise
November 13, 2013, Vancouver, Canada—iCo Therapeutics Inc. (TSX-V: ICO), today announced that subsequent to
iCo Therapeutics to Present at the Ophthalmology Innovation Summit
November 7, 2013, Vancouver, Canada—iCo Therapeutics Inc. (TSX-V: ICO), today announced that Management will
iCo Therapeutics Grants Options to a Director
September 5, 2013, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference
September 4, 2013, Vancouver, Canada—iCo Therapeutics Inc. (TSX-V: ICO), today announced it will be
iCo Therapeutics Announces Second Quarter 2013 Financial Results
August 26, 2013, Vancouver, Canada—iCo Therapeutics (TSX-V: ICO), today reported financial results for the